A Three-part First Time in Human Study to Evaluate Safety, Tolerability, Pharmacokinetics and Food Effect of Single Oral Doses of GSK580416 in Healthy Adult Subjects
Latest Information Update: 01 Aug 2023
At a glance
- Drugs GSK 580416 (Primary)
- Indications Bacterial infections; Respiratory tract infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 08 Jun 2012 New trial record